Rafferty Asset Management, LLC Biotechnology

Rafferty Asset Management, LLC

$22.9 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$119B	$34.3 Million 0.15% of portfolio	70,830	Q1 2025 Reduced 21.49%
REGN Regeneron Pharmaceuticals, Inc.	$59B	$28.4 Million 0.12% of portfolio	44,702	Q1 2025 Reduced 6.1%
ALNY Alnylam Pharmaceuticals, Inc.	$39.9B	$12 Million 0.05% of portfolio	44,585	Q1 2025 Reduced 15.59%
INSM Insmed Inc	$14.1B	$11.1 Million 0.05% of portfolio	145,984	Q1 2025 Reduced 19.31%
UTHR United Therapeutics Corp	$13.5B	$11.1 Million 0.05% of portfolio	35,962	Q1 2025 Reduced 5.57%
INCY Incyte Corp	$15.3B	$10.6 Million 0.05% of portfolio	174,455	Q1 2025 Reduced 14.2%
MDGL Madrigal Pharmaceuticals, Inc.	$5.96B	$9.9 Million 0.04% of portfolio	29,902	Q1 2025 Reduced 9.72%
MRNA Moderna, Inc.	$12.6B	$9.89 Million 0.04% of portfolio	348,859	Q1 2025 Reduced 2.03%
BMRN Biomarin Pharmaceutical Inc	$10.8B	$9.49 Million 0.04% of portfolio	134,218	Q1 2025 Reduced 35.42%
BPMC Blueprint Medicines Corp	$7.73B	$8.79 Million 0.04% of portfolio	99,320	Q1 2025 Added 11.73%
EXEL Exelixis, Inc.	$14.4B	$8.68 Million 0.04% of portfolio	234,972	Q1 2025 Added 7.61%
HALO Halozyme Therapeutics, Inc.	$8.05B	$7.23 Million 0.03% of portfolio	113,289	Q1 2025 Reduced 48.36%
TGTX Tg Therapeutics, Inc.	$5.69B	$7.17 Million 0.03% of portfolio	181,861	Q1 2025 Reduced 45.13%
BBIO Bridge Bio Pharma, Inc.	$6.93B	$6.99 Million 0.03% of portfolio	202,128	Q1 2025 Reduced 19.23%
SRPT Sarepta Therapeutics, Inc.	$1.92B	$6.32 Million 0.03% of portfolio	99,105	Q1 2025 Reduced 9.27%
CYTK Cytokinetics Inc	$3.66B	$6.01 Million 0.03% of portfolio	149,507	Q1 2025 Reduced 10.97%
RVMD Revolution Medicines, Inc.	$3.42B	$5.78 Million 0.03% of portfolio	163,419	Q1 2025 Reduced 5.42%
IONS Ionis Pharmaceuticals Inc	$5.99B	$5.32 Million 0.02% of portfolio	176,248	Q1 2025 Reduced 25.74%
ROIV Roivant Sciences Ltd.	$8.21B	$5.07 Million 0.02% of portfolio	502,951	Q1 2025 Reduced 30.38%
PCVX Vaxcyte, Inc.	$2.22B	$4.98 Million 0.02% of portfolio	131,812	Q1 2025 Reduced 10.6%
CRSP Crispr Therapeutics Ag	$4.3B	$4.97 Million 0.02% of portfolio	146,032	Q1 2025 Reduced 11.93%
SWTX Spring Works Therapeutics, Inc.	$2.93B	$4.9 Million 0.02% of portfolio	110,926	Q1 2025 Reduced 9.77%
VKTX Viking Therapeutics, Inc.	$2.46B	$4.44 Million 0.02% of portfolio	183,769	Q1 2025 Reduced 32.23%
ADMA Adma Biologics, Inc.	$3.45B	$4.43 Million 0.02% of portfolio	223,338	Q1 2025 Reduced 56.48%
SMMT Summit Therapeutics Inc.	$5.6B	$4.43 Million 0.02% of portfolio	229,742	Q1 2025 Reduced 26.29%
KRYS Krystal Biotech, Inc.	$3.85B	$4.36 Million 0.02% of portfolio	24,161	Q1 2025 Reduced 11.18%
RNA Avidity Biosciences, Inc.	$1.77B	$4.27 Million 0.02% of portfolio	144,817	Q1 2025 Reduced 18.18%
APLS Apellis Pharmaceuticals, Inc.	$2.2B	$3.94 Million 0.02% of portfolio	180,134	Q1 2025 Reduced 25.4%
ACLX Arcellx, Inc.	$2.94B	$3.84 Million 0.02% of portfolio	58,507	Q1 2025 Reduced 17.64%
IMVT Immunovant, Inc.	$3.55B	$3.82 Million 0.02% of portfolio	138,837	Q1 2025 Added 19.05%
NUVL Nuvalent, Inc.	$3.68B	$3.63 Million 0.02% of portfolio	51,192	Q1 2025 Reduced 13.64%
SRRK Scholar Rock Holding Corp	$2.21B	$3.59 Million 0.02% of portfolio	111,671	Q1 2025 Added 43.03%
CRNX Crinetics Pharmaceuticals, Inc.	$1.77B	$3.43 Million 0.01% of portfolio	102,131	Q1 2025 Added 25.69%
ACAD Acadia Pharmaceuticals Inc	$3.65B	$3.33 Million 0.01% of portfolio	200,289	Q1 2025 Added 33.32%
VCYT Veracyte, Inc.	$1.73B	$3.29 Million 0.01% of portfolio	110,969	Q1 2025 Added 22.82%
RARE Ultragenyx Pharmaceutical Inc.	$1.92B	$3.22 Million 0.01% of portfolio	88,812	Q1 2025 Reduced 12.32%
RXRX Recursion Pharmaceuticals, Inc.	$996M	$3.17 Million 0.01% of portfolio	598,420	Q1 2025 Added 0.5%
RYTM Rhythm Pharmaceuticals, Inc.	$3.66B	$3.06 Million 0.01% of portfolio	57,732	Q1 2025 Added 14.56%
AKRO Akero Therapeutics, Inc.	$2.52B	$3 Million 0.01% of portfolio	74,081	Q1 2025 Added 2.03%
PTCT Ptc Therapeutics, Inc.	$3.47B	$2.91 Million 0.01% of portfolio	57,067	Q1 2025 Reduced 26.87%
AGIO Agios Pharmaceuticals, Inc.	$2.21B	$2.74 Million 0.01% of portfolio	93,627	Q1 2025 Added 33.16%
TVTX Travere Therapeutics, Inc.	$1.06B	$2.6 Million 0.01% of portfolio	145,021	Q1 2025 Reduced 17.8%
CPRX Catalyst Pharmaceuticals, Inc.	$2.21B	$2.54 Million 0.01% of portfolio	104,699	Q1 2025 Reduced 10.58%
ARQT Arcutis Biotherapeutics, Inc.	$932M	$2.51 Million 0.01% of portfolio	160,367	Q1 2025 Reduced 23.76%
ARWR Arrowhead Pharmaceuticals, Inc.	$2B	$2.46 Million 0.01% of portfolio	192,791	Q1 2025 Added 39.32%
BEAM Beam Therapeutics Inc.	$1.44B	$2.34 Million 0.01% of portfolio	119,871	Q1 2025 Added 7.89%
MIRM Mirum Pharmaceuticals, Inc.	$1.94B	$2.34 Million 0.01% of portfolio	51,857	Q1 2025 Added 14.83%
PTGX Protagonist Therapeutics, Inc	$2.77B	$2.14 Million 0.01% of portfolio	44,257	Q1 2025 Reduced 53.64%
VCEL Vericel Corp	$1.71B	$2.13 Million 0.01% of portfolio	47,696	Q1 2025 Added 14.41%
SNDX Syndax Pharmaceuticals Inc	$547M	$2.11 Million 0.01% of portfolio	171,541	Q1 2025 Reduced 3.72%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.